Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04522323 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
A Phase 1 study of Advanced Renal Cell Carcinoma, sponsored by MedImmune.
- Active
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 20
- Study locations
NCT04522323 is a Phase 1 study of Advanced Renal Cell Carcinoma that is active but no longer recruiting, run by MedImmune. The registered enrollment target is 67 participants, below the 88-participant average among 12 other Advanced Renal Cell Carcinoma trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT04522323, a Phase 1 study of Advanced Renal Cell Carcinoma, is active but no longer recruiting, sponsored by MedImmune.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.
Conditions Studied
Interventions
- DRUG Lenvatinib
- DRUG Axitinib
- BIOLOGICAL MEDI5752
Study Locations (20)
Other
- Research Site - Frankston
- Research Site - Waratah
- Research Site - Villejuif
- Research Site - Barcelona
- Research Site - Barcelona
- Research Site - Barcelona
- Research Site - Barcelona
- Research Site - Córdoba
- Research Site - Madrid
- Research Site - Madrid
- Research Site - Sabadell
- Research Site - Seville
- Research Site - Valencia
District of Columbia
- Research Site - Washington D.C.
Florida
- Research Site - Fort Myers
Missouri
- Research Site - St Louis
New York
- Research Site - New York
Ohio
- Research Site - Cleveland
Pennsylvania
- Research Site - Hershey
Tennessee
- Research Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2020-08-05 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04522323
The ClinicalTrials.gov registry entry for NCT04522323 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 12 other Advanced Renal Cell Carcinoma trials with a reported enrollment target (24% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Lenvatinib is the first listed.
NCT04522323 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT04522323 about?
NCT04522323 is a clinical study titled "A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma". The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.
What is the current status of trial NCT04522323?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2020-08-05. Estimated completion is 2025-09-26.
What conditions does trial NCT04522323 study?
This clinical trial studies the following conditions: Advanced Renal Cell Carcinoma.
What interventions are being tested in trial NCT04522323?
The interventions under investigation include: Lenvatinib (DRUG), Axitinib (DRUG), MEDI5752 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04522323?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04522323 being conducted?
This trial has 20 study locations across District of Columbia, Florida, Missouri, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
RECRUITING · Phase 1
-
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
RECRUITING · Phase 1
-
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
RECRUITING · Phase 1
-
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.